Will AstraZeneca shares move higher after China Covid-19 vaccine deal?

The British-Swedish drug maker has seen its share price perform well in 2020. But will the company’s stock push even higher after securing the first coronavirus vaccine deal with China?

AstraZeneca has trended lower this week, returning to levels seen throughout June after the stock rallied to an all-time high of £93.20 per share in mid-July. However, the drug maker is well-positioned to see its shares soar once again after signing the first Covid-19 vaccine deal with China.

The deal will see China-based Shenzhen Kangtai Biological Products produce AstraZeneca’s potential Covid-19 vaccine in mainland China – securing the drug maker's pole position in the global race to deliver a cure for the coronavirus pandemic.

AstraZeneca is trading at £83.16 per share at the time of publication, with the stock up 9% year-to-date.

AstraZeneca: outlook for 2020

AstraZeneca CEO Pascal Soriot praised his employees for the company’s strong performance in its half-year (H1) results at the end of July, with the business delivering further revenue growth that has helped improve profitability and cash generation.

The drug maker has performed particularly well in emerging markets and has seen success with its newly developed medicines, along with the company becoming a leader in the fight against Covid-19.

‘Looking ahead, while we continue to anticipate variations in quarterly performance, the continuation of our strategy makes us confident about the future,’ Soriot said.

‘We are retaining our full-year guidance that is underpinned by the focus on commercial execution and an exciting pipeline of new medicines,’ he added.

Total revenue is expected to increase by a high single-digit to a low double-digit percentage in 2020 and core earnings per share is expected to increase by a mid- to high-teens percentage, according to AstraZeneca’s own guidance which has been left unchanged.

AstraZeneca-Oxford University Covid-19 vaccine produces immune response

AstraZeneca shares are likely to get a boost after its partnership with Oxford University has shown promising results from early stage trials for a potential coronavirus vaccine.

In fact, a new study published earlier this month in the scientific journal, The Lancet, showed that a team of scientists from Oxford University’s Jenner Institute and Oxford Vaccine Group have created a Covid-19 vaccine that induces a strong immune response to the virus.

'We are encouraged by the Phase I/II interim data showing AZD1222 was capable of generating a rapid antibody and T-cell response against SARS-CoV-2,’ Mene Pangalos, executive vice-president of BioPharmaceuticals R&D at AstraZeneca, said.

‘While there is more work to be done, today’s data increases our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access around the world,’ he added.

How to trade stocks with IG

Looking to trade AstraZeneca and other stocks? Open a live or demo account with IG and buy (long) or sell (short) shares using derivatives like CFDs in a few easy steps:

  1. Create an IG trading account or log in to your existing account
  2. Enter ‘AstraZeneca’ in the search bar and select it
  3. Choose your position size
  4. Click on ‘buy’ or ‘sell’ in the deal ticket
  5. Confirm the trade

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.